Personalized vitamin d dosing may beat standard approach in breast cancer patients

NCT ID NCT01480869

Completed Disease control Sponsor: Institut du Cancer de Montpellier - Val d'Aurelle Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether giving vitamin D based on a patient's deficiency level works better than a standard dose. 215 breast cancer patients on chemotherapy received either a fixed daily supplement or a tailored dose. The goal was to see which method normalizes vitamin D levels faster and more safely.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: vitamin D and calcium supplements
What this could lead to: If successful, this could show that personalized vitamin D dosing is better at correcting deficiencies in breast cancer patients, potentially improving bone health and overall well-being during chemotherapy.
What could go wrong: This trial is completed and focuses on vitamin D levels, not cancer outcomes. It may not affect cancer recurrence or survival, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast adenocarcinoma breast cancer breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

CRLC Val d'Aurelle-Paul Lamarque

Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.